Off Patent
January 2026

Promacta

eltrombopag olamine

Novartis Pharmaceuticals Corp

Tablet (oral) · NDA 022291

Last listed protection ended
January 13, 2026

The FDA listed 1 patent and 1 exclusivity for Promacta, and this is the day the last one ended. It is not the date a generic goes on sale.

Patents and exclusivities

  1. Ended
    Patent 7,547,719
    Claims the drug substance, the drug product and a use (U-1306, U-1575, U-2451, U-2452, U-930)
  2. Ended
    Orphan drug exclusivity
    FDA code ODE-210
  3. Ended
    Patent 7,547,719
    Pediatric extension: six more months